Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development

Chemomab Therapeutics Ltd.

Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.
Annual base salary of $450,000; target performance bonus of 45% of base salary.
Special milestone bonuses: $100,000 after 60 days, $100,000 after 120 days.
Granted option to purchase 125,000 ADSs vesting over 4 years (25% annual, rest monthly).
Employment is at-will; governed by New York law with mandatory arbitration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.